DBV Technologies S.A. (DBV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DBV Technologies S.A. (DBV) has a cash flow conversion efficiency ratio of -0.236x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-49.10 Million ≈ $-57.40 Million USD) by net assets (€207.90 Million ≈ $243.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of DBV Technologies S.A. to measure how much of total assets are equity-financed.
DBV Technologies S.A. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DBV Technologies S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore DBV long-term investments to assets to see how much of total assets are deployed in long-term investments.
DBV Technologies S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Medsys Tech Co Ltd
SHG:603990
|
0.021x |
|
Anhui Sierte Fertilizer Industry Ltd Co
SHE:002538
|
0.024x |
|
BMC Medical Co. Ltd. A
SHE:301367
|
N/A |
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
0.159x |
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
0.057x |
|
Jiangmen iDear-Hanyu Electrical Joint-Stock Co Ltd
SHE:300403
|
0.033x |
|
INKON Life Technology Co Ltd
SHE:300143
|
0.027x |
|
Xinjiang Qingsong Building Materials and Chemicals Group Co Ltd
SHG:600425
|
0.028x |
Annual Cash Flow Conversion Efficiency for DBV Technologies S.A. (2011–2025)
The table below shows the annual cash flow conversion efficiency of DBV Technologies S.A. from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see DBV stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €168.79 Million ≈ $197.33 Million |
€-126.12 Million ≈ $-147.45 Million |
-0.747x | +80.41% |
| 2024-12-31 | €27.39 Million ≈ $32.02 Million |
€-104.47 Million ≈ $-122.14 Million |
-3.815x | -571.38% |
| 2023-12-31 | €140.19 Million ≈ $163.89 Million |
€-79.65 Million ≈ $-93.12 Million |
-0.568x | -98.41% |
| 2022-12-31 | €194.50 Million ≈ $227.39 Million |
€-55.70 Million ≈ $-65.12 Million |
-0.286x | +73.74% |
| 2021-12-31 | €99.27 Million ≈ $116.06 Million |
€-108.24 Million ≈ $-126.55 Million |
-1.090x | -65.92% |
| 2020-12-31 | €252.01 Million ≈ $294.62 Million |
€-165.61 Million ≈ $-193.61 Million |
-0.657x | +12.28% |
| 2019-12-31 | €218.05 Million ≈ $254.92 Million |
€-163.34 Million ≈ $-190.96 Million |
-0.749x | +33.50% |
| 2018-12-31 | €165.78 Million ≈ $193.81 Million |
€-186.74 Million ≈ $-218.32 Million |
-1.126x | -28.02% |
| 2017-12-31 | €182.88 Million ≈ $213.81 Million |
€-160.91 Million ≈ $-188.12 Million |
-0.880x | -258.89% |
| 2016-12-31 | €267.90 Million ≈ $313.21 Million |
€-65.68 Million ≈ $-76.79 Million |
-0.245x | -195.04% |
| 2015-12-31 | €384.24 Million ≈ $449.21 Million |
€-31.93 Million ≈ $-37.33 Million |
-0.083x | +53.34% |
| 2014-12-31 | €182.22 Million ≈ $213.04 Million |
€-32.45 Million ≈ $-37.94 Million |
-0.178x | +45.72% |
| 2013-12-31 | €74.09 Million ≈ $86.61 Million |
€-24.31 Million ≈ $-28.42 Million |
-0.328x | -23.20% |
| 2012-12-31 | €66.84 Million ≈ $78.15 Million |
€-17.80 Million ≈ $-20.81 Million |
-0.266x | +49.14% |
| 2011-12-31 | €19.79 Million ≈ $23.13 Million |
€-10.36 Million ≈ $-12.11 Million |
-0.524x | -- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more